CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC 50 of 520 nM
In Vivo
CCT369260 (compound 1, 15 mg/kg, po, single dose) significantly inhibits BCL6 in OCI-Ly1 DLBCL xenograft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: OCI-Ly1 DLBCL xenograft model (female SCID mice) . Dosage: 15 mg/kg. Administration: PO, single dose. Result: Decreased the levels of BCL6 in the tumor observed up to 10 h after administration. Animal Model: Female Balb/C mice . Dosage: 1 mg/kg iv and 5 mg/kg po (Pharmacokinetic Analysis). Administration: IV and PO Result: Demonstrated moderate clearance (CL 20 mL min −1 kg −1 ) with mean oral bioavailability of 54%.
IC50& Target:IC50: 520 nM (BCL6)
사양
사양 및 순도
10mM in DMSO
생화학 및 생리적 메커니즘
CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC 50 of 520 nM.
보관 조건
Store at -80°C
배송
Dry ice packs + Cold packs
이 제품은 콜드 체인 배송이 필요합니다.지상 및 기타 경제 서비스는 사용할 수 없습니다.
작업 유형
INHIBITOR
이름과 식별자
분자량
508.99
고급 데이터
인증서(CoA, COO, BSE/TSE 및 분석 차트)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
솔루션 계산기
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.